MEA Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Middle East and Africa syndromic multiplex diagnostic market is projected to register a CAGR of 6.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029.

Market Segmentation:

Middle East and Africa Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of Middle East and Africa syndromic multiplex diagnostic market are:

Increase in prevalence of infectious diseases

Growing technological advancement

Strategic initiatives

Market Players:

The major companies which are dealing in the Middle East and Africa syndromic multiplex diagnostic are listed below:

BioFire Diagnostics (A Subsidiary of bioMerieux SA)

Seegene Inc.

Luminex Corporation. A DiaSorin Company

F. Hoffmann-La Roche Ltd

Bio-Rad Laboratories, Inc.

Cepheid (A Subsidiary of Danaher)

QIAGEN

Abbott

Hologic, Inc.

Thermo Fisher Scientific Inc.

Siemens Healthcare GmbH

Biocartis

QuantuMDx Group Ltd.

Prominex Inc.

Curetis (A Subsidiary of OpGen, Inc.)

1 INTRODUCTION 27

1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29

2 MARKET SEGMENTATION 32

2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 46

4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50

5 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51

6 MARKET OVERVIEW 54

6.1 DRIVERS 56
- 6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
- 6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
- 6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
- 6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58
6.2 RESTRAINTS 59
- 6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
- 6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
- 6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
- 6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
- 6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
- 6.4.1 PRODUCT RECALLS 63
- 6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63

7 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64

7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69

8 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71

8.1 OVERVIEW 72
8.2 VIRAL 75
- 8.2.1 CORONAVIRUS 76
- 8.2.2 INFLUENZA VIRUS 76
- 8.2.3 ADENOVIRUS 76
- 8.2.4 RHINOVIRUS 76
- 8.2.5 ROTAVIRUS 76
- 8.2.6 OTHERS 76
8.3 BACTERIAL 77
- 8.3.1 PNEUMONIAE 78
- 8.3.2 BORDETELLA PERTUSSIS 78
- 8.3.3 STAPHYLOCOCCUS 78
- 8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79

9 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81

9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89

10 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91

10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99

11 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100

11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107

12 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108

12.1 MIDDLE EAST AND AFRICA 109
- 12.1.1 SOUTH AFRICA 116
- 12.1.2 SAUDI ARABIA 119
- 12.1.3 U.A.E 122
- 12.1.4 ISRAEL 125
- 12.1.5 EGYPT 128
- 12.1.6 REST OF MIDDLE EAST AND AFRICA 131

13 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 132

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 132

14 SWOT ANALYSIS 133

15 COMPANY PROFILE 134

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMERIEUX SA) 134
- 15.1.1 COMPANY SNAPSHOT 134
- 15.1.2 REVENUE ANALYSIS 134
- 15.1.3 COMPANY SHARE ANALYSIS 135
- 15.1.4 PRODUCT PORTFOLIO 135
- 15.1.5 RECENT DEVELOPMENTS 136
15.2 F. HOFFMANN-LA ROCHE LTD 137
- 15.2.1 COMPANY SNAPSHOT 137
- 15.2.2 REVENUE ANALYSIS 137
- 15.2.3 COMPANY SHARE ANALYSIS 138
- 15.2.4 PRODUCT PORTFOLIO 138
- 15.2.5 RECENT DEVELOPMENT 139
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 140
- 15.3.1 COMPANY SNAPSHOT 140
- 15.3.2 RECENT FINANCIALS 140
- 15.3.3 COMPANY SHARE ANALYSIS 141
- 15.3.4 PRODUCT PORTFOLIO 141
- 15.3.5 RECENT DEVELOPMENT 142
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 143
- 15.4.1 COMPANY SNAPSHOT 143
- 15.4.2 RECENT FINANCIALS 143
- 15.4.3 COMPANY SHARE ANALYSIS 144
- 15.4.4 PRODUCT PORTFOLIO 144
- 15.4.5 RECENT DEVELOPMENTS 145
15.5 QIAGEN 146
- 15.5.1 COMPANY SNAPSHOT 146
- 15.5.2 RECENT FINANCIALS 146
- 15.5.3 COMPANY SHARE ANALYSIS 147
- 15.5.4 PRODUCT PORTFOLIO 147
- 15.5.5 RECENT DEVELOPMENT 147
15.6 ABBOTT 148
- 15.6.1 COMPANY SNAPSHOT 148
- 15.6.2 REVENUE ANALYSIS 148
- 15.6.3 PRODUCT PORTFOLIO 149
- 15.6.4 RECENT DEVELOPMENT 149
15.7 AKONNI BIOSYSTEMS, INC. 150
- 15.7.1 COMPANY SNAPSHOT 150
- 15.7.2 PRODUCT PORTFOLIO 150
- 15.7.3 RECENT DEVELOPMENT 150
15.8 APPLIED BIOCODE, INC. 151
- 15.8.1 COMPANY SNAPSHOT 151
- 15.8.2 PRODUCT PORTFOLIO 151
- 15.8.3 RECENT DEVELOPMENTS 152
15.9 BD 153
- 15.9.1 COMPANY SNAPSHOT 153
- 15.9.2 REVENUE ANALYSIS 153
- 15.9.3 PRODUCT PORTFOLIO 154
- 15.9.4 RECENT DEVELOPMENTS 154
15.10 BIOCARTIS 155
- 15.10.1 COMPANY SNAPSHOT 155
- 15.10.2 REVENUE ANALYSIS 155
- 15.10.3 PRODUCT PORTFOLIO 156
- 15.10.4 RECENT DEVELOPMENT 156
15.11 BIO-RAD LABORATORIES, INC. 157
- 15.11.1 COMPANY SNAPSHOT 157
- 15.11.2 REVENUE ANALYSIS 157
- 15.11.3 PRODUCT PORTFOLIO 158
- 15.11.4 RECENT DEVELOPMENT 158
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 159
- 15.12.1 COMPANY SNAPSHOT 159
- 15.12.2 REVENUE ANALYSIS 159
- 15.12.3 PRODUCT PORTFOLIO 160
- 15.12.4 RECENT DEVELOPMENT 160
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 161
- 15.13.1 COMPANY SNAPSHOT 161
- 15.13.2 RECENT FINANCIALS 161
- 15.13.3 PRODUCT PORTFOLIO 162
- 15.13.4 RECENT DEVELOPMENTS 162
15.14 HOLOGIC, INC. 163
- 15.14.1 COMPANY SNAPSHOT 163
- 15.14.2 RECENT FINANCIALS 163
- 15.14.3 PRODUCT PORTFOLIO 164
- 15.14.4 RECENT DEVELOPMENT 164
15.15 MIRXES PTE LTD. 165
- 15.15.1 COMPANY SNAPSHOT 165
- 15.15.2 PRODUCT PORTFOLIO 165
- 15.15.3 RECENT DEVELOPMENT 165
15.16 NANOMIX, INC. 166
- 15.16.1 COMPANY SNAPSHOT 166
- 15.16.2 PRODUCT PORTFOLIO 166
- 15.16.3 RECENT DEVELOPMENT 166
15.17 PROMINEX INC. 167
- 15.17.1 COMPANY SNAPSHOT 167
- 15.17.2 PRODUCT PORTFOLIO 167
- 15.17.3 RECENT DEVELOPMENT 167
15.18 QUANTUMDX GROUP LTD. 168
- 15.18.1 COMPANY SNAPSHOT 168
- 15.18.2 PRODUCT PORTFOLIO 168
- 15.18.3 RECENT DEVELOPMENTS 168
15.19 SEEGENE INC. 169
- 15.19.1 COMPANY SNAPSHOT 169
- 15.19.2 REVENUE ANALYSIS 169
- 15.19.3 PRODUCT PORTFOLIO 170
- 15.19.4 RECENT DEVELOPMENTS 173
15.20 SIEMENS HEALTHCARE GMBH 174
- 15.20.1 COMPANY SNAPSHOT 174
- 15.20.2 RECENT FINANCIALS 174
- 15.20.3 PRODUCT PORTFOLIO 175
- 15.20.4 RECENT DEVELOPMENT 175
15.21 THERMOFISHER SCIENTIFIC INC. 176
- 15.21.1 COMPANY SNAPSHOT 176
- 15.21.2 RECENT FINANCIALS 176
- 15.21.3 PRODUCT PORTFOLIO 177
- 15.21.4 RECENT DEVELOPMENT 177

16 QUESTIONNAIRE 178

17 RELATED REPORTS 181

LIST OF TABLES

TABLE 1 COST OF THE PRODUCT 49
TABLE 2 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION) 57
TABLE 3 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 58
TABLE 4 MIDDLE EAST & AFRICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 59
TABLE 5 MIDDLE EAST & AFRICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 60
TABLE 6 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 64
TABLE 7 MIDDLE EAST & AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 65
TABLE 8 MIDDLE EAST & AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 66
TABLE 9 MIDDLE EAST & AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 67
TABLE 10 MIDDLE EAST & AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 68
TABLE 11 MIDDLE EAST & AFRICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 69
TABLE 12 MIDDLE EAST & AFRICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 13 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 74
TABLE 14 MIDDLE EAST & AFRICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 75
TABLE 15 MIDDLE EAST & AFRICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 76
TABLE 16 MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 77
TABLE 17 MIDDLE EAST & AFRICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 18 MIDDLE EAST & AFRICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 19 MIDDLE EAST & AFRICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 20 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 84
TABLE 21 MIDDLE EAST & AFRICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 85
TABLE 22 MIDDLE EAST & AFRICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 86
TABLE 23 MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 24 MIDDLE EAST & AFRICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 25 MIDDLE EAST & AFRICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 26 MIDDLE EAST & AFRICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 27 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 93
TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 94
TABLE 29 MIDDLE EAST & AFRICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 95
TABLE 30 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 31 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION) 97
TABLE 33 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 103
TABLE 34 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 103
TABLE 35 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 103
TABLE 36 MIDDLE EAST AND AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 104
TABLE 37 MIDDLE EAST AND AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 104
TABLE 38 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 104
TABLE 39 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 105
TABLE 40 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 105
TABLE 41 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 106
TABLE 42 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 106
TABLE 43 SOUTH AFRICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 106
TABLE 44 SOUTH AFRICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 107
TABLE 45 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 107
TABLE 46 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 107
TABLE 47 SOUTH AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 108
TABLE 48 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 109
TABLE 49 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 109
TABLE 50 SAUDI ARABIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 109
TABLE 51 SAUDI ARABIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 110
TABLE 52 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 110
TABLE 53 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 110
TABLE 54 SAUDI ARABIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 111
TABLE 55 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 112
TABLE 56 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 112
TABLE 57 U.A.E VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 112
TABLE 58 U.A.E BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 113
TABLE 59 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 113
TABLE 60 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 113
TABLE 61 U.A.E SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 114
TABLE 62 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 115
TABLE 63 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 115
TABLE 64 ISRAEL VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 115
TABLE 65 ISRAEL BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 116
TABLE 66 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 116
TABLE 67 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 116
TABLE 68 ISRAEL SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 117
TABLE 69 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 118
TABLE 70 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 118
TABLE 71 EGYPT VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 118
TABLE 72 EGYPT BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION) 119
TABLE 73 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION) 119
TABLE 74 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION) 119
TABLE 75 EGYPT SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION) 120
TABLE 76 REST OF MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION) 121

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 21
FIGURE 2 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION 24
FIGURE 3 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS 25
FIGURE 4 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 26
FIGURE 5 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 26
FIGURE 6 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 29
FIGURE 8 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID 30
FIGURE 9 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 31
FIGURE 10 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION 34
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD 35
FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029 35
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 36
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 44
FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA 45
FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE 46
FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019 50
FIGURE 18 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021 54
FIGURE 19 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION) 55
FIGURE 20 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029) 55
FIGURE 21 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE 56
FIGURE 22 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021 61
FIGURE 23 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION) 62
FIGURE 24 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029) 62
FIGURE 25 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE 63
FIGURE 26 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021 71
FIGURE 27 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION) 72
FIGURE 28 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029) 72
FIGURE 29 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE 73
FIGURE 30 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021 81
FIGURE 31 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION) 82
FIGURE 32 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029) 82
FIGURE 33 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE 83
FIGURE 34 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021 90
FIGURE 35 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION) 91
FIGURE 36 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029) 91
FIGURE 37 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 92
FIGURE 38 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021) 99
FIGURE 39 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021) 100
FIGURE 40 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029) 100
FIGURE 41 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029) 101
FIGURE 42 MIDDLE EAST AND AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029) 101
FIGURE 43 MIDDLE EAST & AFRICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%) 121